Multivariate analysis to identify independent variables that predict ESLD development in patients with SSc-ILD.
| Variables at Diagnosis | OR (95% CI), p | OR (95% CI), p, Adjusted for Age and Smoking |
|---|---|---|
| dcSSc | 5.57 (0.86–36.1), p = 0.07 | 4.64 (0.62–34.7), p = 0.14 |
| mRSS | 0.96 (0.79–1.18), p = 0.71 | 0.91 (0.73–1.14), p = 0.41 |
| Exertional dyspnea | 1.91 (0.11–34.0), p = 0.66 | 1.93 (0.81–45.9), p = 0.68 |
| Anti-topo I antibody | 0.84 (0.04–17.5), p = 0.91 | 1.70 (0.09–33.7), p = 0.73 |
| FVC | 1.01 (0.89–1.15), p = 0.84 | 1.00 (0.87–1.14), p = 0.97 |
| DLCO | 0.94 (0.86–1.03), p = 0.20 | 0.97 (0.87–1.08), p = 0.57 |
| Serum KL-6 > 1273 U/ml | 51.2 (7.6–343), p < 0.0001 | 80.1 (10.0–642), p < 0.0001 |
ESLD: endstage lung disease; SSc: systemic sclerosis; dcSSc: diffuse cutaneous SSc; ILD: interstitial lung disease; mRSS: modified Rodnan skin score; anti-topo I: antitopoisomerase I; FVC: forced vital capacity; KL-6: Krebs von den Lungen-6.